Brodalumab-associated generalized eczematous eruption in a difficult-to-treat psoriasis patient: management without brodalumab withdrawal

Eur J Dermatol. 2020 Dec 1;30(6):741-743. doi: 10.1684/ejd.2020.3910.

Authors

Marie Danset¹, Florence Hacard², Coline Jaulent², Audrey Nosbaum², Frédéric Berard², Jean-François Nicolas², Catherine Goujon¹

Affiliations

¹ Allergy and Clinical Immunology Department, Lyon Sud University Hospital, Hospices Civils de Lyon, Pierre Bénite, France.
² Allergy and Clinical Immunology Department, Lyon Sud University Hospital, Hospices Civils de Lyon, Pierre Bénite, France, CIRI (International Center for Infectiology Research), INSERM U1111, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5308, 21 Avenue Tony Garnier, 69007 Lyon, France.

PMID: 33337328
DOI: 10.1684/ejd.2020.3910

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / adverse effects*
Dermatologic Agents / administration & dosage
Dermatologic Agents / adverse effects*
Drug Administration Schedule
Drug Eruptions / etiology*
Eczema / chemically induced*
Humans
Interleukin-17 / antagonists & inhibitors*
Male
Middle Aged
Psoriasis / drug therapy*

Substances

Antibodies, Monoclonal, Humanized
Dermatologic Agents
Interleukin-17
brodalumab